Search
Vorapaxar
go.drugbank.com/drugs/DB09030ApprovedVorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history … By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-{(E)-2-[5-(3-Fluorophényl)-2-pyridinyl]vinyl}-1-méthyl-3-oxododécahydronaphto[2,3-c]furan-6-yl]carbamate d'éthyle, Carbamic acid, N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)-2-pyridinyl]ethenyl]dodecahydro-1-methyl-3-oxonaphtho[2,3-c]furan-6-yl]-, ethyl esterMiltefosine
go.drugbank.com/drugs/DB09031ApprovedInvestigationalMiltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. … The CDC has also recommended it as a first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and granulomatous amebic encephalitis.
Categories: P-glycoprotein substratesSynonyms: hexadecyl 2-(trimethylazaniumyl)ethyl phosphateAlbiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). … It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA.
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsNaloxegol
go.drugbank.com/drugs/DB09049ApprovedInvestigationalNaloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. … It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 InhibitorsSynonyms: (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diolAnthrax immune globulin human
go.drugbank.com/drugs/DB09057ApprovedInvestigationalAnthrax immune globulin is a human antibody given with antibiotics for the treatment of anthrax. … It is derived from the plasma of humans immunized with BioThrax (adsorbed anthrax vaccine), which is then further purified.
Olaparib
go.drugbank.com/drugs/DB09074ApprovedInvestigationalOlaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. … [A246015] Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.
Categories: MATE 2-K Inhibitors, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-oneEdoxaban
go.drugbank.com/drugs/DB09075ApprovedInvestigationalEdoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. … It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism
Categories: P-glycoprotein substrates, Heterocyclic Compounds, 1-RingNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigationalbeing [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function. … [A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459]
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesSynonyms: methyl (3Z)-3-[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino}anilino)(phenyl)methylidene]-2-oxo-2,3-dihydro-1H-indole-6-carboxylateOlodaterol
go.drugbank.com/drugs/DB09080ApprovedInvestigationalA once-a-day treatment with a LABA has several advantages over short-acting bronchodilators and twice-daily LABAs including improved convenience and compliance and improved airflow over a 24-hour period … It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it.
Mixtures: SPIOLTO®RESPIMAT®, SPIOLTO®RESPIMAT®Categories: Cytochrome P-450 Substrates, Adrenergic beta-1 Receptor AgonistsIvabradine
go.drugbank.com/drugs/DB09083ApprovedInvestigationalTherefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing … Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure.
Mixtures: CARIVALAN 25/5, CARIVALAN 6.25/5Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 2-Ring